ProShares Trust - ProShares Short QQQ -1x Shares
PSQ
Get informed when a big investor buys or sells
+ FollowShare Statistics
| Market cap | $25.80 Billion |
|---|---|
| Enterprise Value | $25.62 Billion |
| Dividend Yield | $1.31 (4.37%) |
| Earnings per Share | $- |
| Beta | -1.14 |
| Outstanding Shares | - |
Return
| Return on Equity | -25.93% |
|---|---|
| Return on Assets | -23.92% |
| Return on Invested Capital | -27.36% |
Valuation & Multiples
| P/E Ratio | - |
|---|---|
| PEG | - |
| Price to Sales | - |
| Price to Book Ratio | - |
| Enterprise Value to Revenue | 1962.05 |
| Enterprise Value to EBIT | -340.86 |
| Enterprise Value to Net Income | -364 |
| Total Debt to Enterprise | 0 |
| Debt to Equity | 0.04 |
Revenue Sources
No data
Insider Trades
Institutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 1.2051▲ 118.04% |
|---|---|
| Total Calls | 237,900▼ 72.91% |
| Total Puts | 286,700▲ 1221.20% |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 39.63%▲ 15.79% |
|---|---|
| Total Invested | $362.85M▲ 122.85% |
| Investors Holding | 99▲ 16.00% |
ESG Score
No data
About BioAge Labs, Inc.
62 employees
CEO: Dr. Kristen Fortney Ph.D. BioAge Labs, Inc. is a clinical-stage biopharmaceutical company that develops therapeutic product candidates for metabolic diseases. The company's technology platform and differentiated human datasets allows users to identify targets bas...
Relevant Senate Committees
This committee directly impacts corporate taxation, which affects profitability, and has significant influence over healthcare entitlement programs like Medicare, which will be a major payer for BioAge Labs' drugs once commercialized, especially given its focus on older adults.
This committee directly oversees the FDA, which is responsible for drug approval, and the NIH, a major funder of biomedical research. Its legislative actions and oversight directly impact BioAge Labs' R&D environment, clinical trial pathways, and ultimate market access for its therapeutic candidates.
This committee has direct oversight over intellectual property laws (patents), which are foundational to the valuation and competitive advantage of a biopharmaceutical company. It also impacts antitrust issues and potential M&A activities in the sector.
BioAge Labs explicitly targets 'obesity in older adults' and diseases driven by neuroinflammation, which are highly relevant to this committee's purview. Its discussions on drug pricing and healthcare access for older Americans could directly impact the future commercial viability and market for BioAge Labs' products.